Acurx Pharmaceuticals, Inc. (ACXP) stock
ACXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.96−0.03 (-2.54%)
Close on Nov 13, 2026Market cap $5.06MP/E –Yield –
Acurx Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Acurx Pharmaceuticals's cash was $9.65M at Sep 30, 2026. For fiscal 2025 it was $7.56M, up 103.8% from the year before. The highest annual figure on record is $12.96M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.56M | +103.8% |
| FY2024 | Dec 31, 2024 | $3.71M | -50.4% |
| FY2023 | Dec 31, 2023 | $7.47M | -18.0% |
| FY2022 | Dec 31, 2022 | $9.11M | -29.7% |
| FY2021 | Dec 31, 2021 | $12.96M | +308.1% |
| FY2020 | Dec 31, 2020 | $3.18M | +27.9% |
| FY2019 | Dec 31, 2019 | $2.48M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $9.65M | +63.4% |
| Q2 FY2026 | Jun 30, 2026 | $10.66M | +75.7% |
| Q1 FY2026 | Mar 31, 2026 | $9.25M | +99.3% |
| Q4 FY2025 | Dec 31, 2025 | $7.56M | +103.8% |
| Q3 FY2025 | Sep 30, 2025 | $5.91M | +2.5% |
| Q2 FY2025 | Jun 30, 2025 | $6.06M | -4.7% |
| Q1 FY2025 | Mar 31, 2025 | $4.64M | -47.9% |
| Q4 FY2024 | Dec 31, 2024 | $3.71M | -50.4% |
| Q3 FY2024 | Sep 30, 2024 | $5.76M | -18.3% |
| Q2 FY2024 | Jun 30, 2024 | $6.36M | -30.5% |
| Q1 FY2024 | Mar 31, 2024 | $8.92M | +24.3% |
| Q4 FY2023 | Dec 31, 2023 | $7.47M | -18.0% |
| Q3 FY2023 | Sep 30, 2023 | $7.05M | -33.5% |
| Q2 FY2023 | Jun 30, 2023 | $9.15M | +0.6% |
| Q1 FY2023 | Mar 31, 2023 | $7.18M | -35.2% |
| Q4 FY2022 | Dec 31, 2022 | $9.11M | -29.7% |
| Q3 FY2022 | Sep 30, 2022 | $10.61M | -26.6% |
| Q2 FY2022 | Jun 30, 2022 | $9.09M | -46.8% |
| Q1 FY2022 | Mar 31, 2022 | $11.08M | +321.7% |
| Q4 FY2021 | Dec 31, 2021 | $12.96M | +308.1% |
| Q3 FY2021 | Sep 30, 2021 | $14.46M | +324.4% |
| Q2 FY2021 | Jun 30, 2021 | $17.10M | +765.8% |
| Q1 FY2021 | Mar 31, 2021 | $2.63M | +5.8% |
| Q4 FY2020 | Dec 31, 2020 | $3.18M | – |
| Q3 FY2020 | Sep 30, 2020 | $3.41M | – |
| Q2 FY2020 | Jun 30, 2020 | $1.97M | – |
| Q4 FY2019 | Dec 31, 2019 | $2.48M | – |
See a number that looks wrong?